53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details

臨床試験数 : 283 / 薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05113004 (ClinicalTrials.gov)	January 5, 2022	2/11/2021	New Clinical End-points in Patients With Primary Sjögren's Syndrome	NEw Clinical Endpoints in Patients With Primary Sjögren's Syndrome (pSS): an Interventional Trial Based on stratifYing Patients	Primary Sjögren's Syndrome (pSS)	Drug: Hydroxychloroquine 400mg/d;Drug: Leflunomide 20mg/d;Drug: Mycophenolate mofetil 2000mg/d;Drug: Placebo of Hydroxychloroquine 400mg/d;Drug: Placebo of Leflunomide 20mg/d;Drug: Placebo of Mycophenolate mofetil 2000mg/d	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	18 Years	N/A	All	300	Phase 2	NULL
2	EUCTR2019-002470-32-IT (EUCTR)	05/10/2021	27/01/2022	Nuovi end-points clinici in pazienti con sindrome di Sjögren primaria (pSS): uno studio interventistico basato sulla stratificazione dei pazienti.	NEw Clinical End-points in patients with primary Sjögren's Syndrome (pSS): an Interventional Trial based on stratifYing patients - NECESSITY	Primary Sjögren's syndrome (pSS) MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Arava Product Name: Leflunomide Product Code: [Leflunomide] INN or Proposed INN: LEFLUNOMIDE Trade Name: Mycophenolate mofetil TEVA Product Name: mycophenolate mofetil Product Code: [mycophenolate mofetil] INN or Proposed INN: MICOFENOLATO MOFETILE Trade Name: PLAQUENIL Product Name: Hydroxychloroquine Product Code: [Hydroxychloroquine] INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE	ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	France;Greece;Spain;Norway;Netherlands;United Kingdom;Italy;Sweden
3	EUCTR2020-001933-11-NL (EUCTR)	10/06/2021	04/06/2021	Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome	Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome - RepurpSS-II study	Primary Sjogren Syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Leflunomide Product Name: Leflunomide Trade Name: Plaquenil Product Name: Hydroxychloroquine	University Medical Center Utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	Netherlands
4	EUCTR2014-003140-12-NL (EUCTR)	21/09/2015	26/08/2015	Leflunomide and Hydroxychloroquine combination therapy for primary Sjogren's Syndrome	Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome - LEF-HCQ combination therapy in pSS	Sjogren's Syndrome MedDRA version: 18.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 18.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;Classification code 10042846;Term: Syndrome Sjogren's;Classification code 10040765;Term: Sjogren's;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Leflunomide Mylan Product Name: Leflunomide mylan INN or Proposed INN: LEFLUNOMIDE Trade Name: Plaquenil Product Name: Plaquenil INN or Proposed INN: HYDROXYCHLOROQUINE	UMC Utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no			Netherlands